Good manufacturing practice-compliant validation and preparation of BM cells for the therapy of acute myocardial infarction

Cytotherapy

Volumn 9, Issue 1, 2007, Pages 35-43

  Griesel, C ^a   Heuft, H G ^a,b   Herrmann, D ^c   Franke, A ^a   Ladas, D ^a   Stiehler, N ^a   Stucki, A ^a   Braun, M ^c   Wollert, K C ^b   Meyer, G P ^b   Drexler, H ^b   Hertenstein, B ^b   Ganser, A ^b   Rudinger W ^a,c   Arseniev, L ^a,b  

^a Cytonet Hannover GmbH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Cytonet GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HETASTARCH; POTASSIUM;

ACUTE HEART INFARCTION; ARTICLE; BACTERIUM CONTAMINATION; BLOOD SAMPLING; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD34 SELECTION; CELL ISOLATION; CELL VOLUME; CONTROLLED STUDY; ERYTHROCYTE COUNT; FLOW KINETICS; GERMANY; GOOD MANUFACTURING PRACTICE; HEMATOCRIT; HUMAN; INSTRUMENT STERILIZATION; LICENCE; MATERIALS HANDLING; METHODOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; SEDIMENTATION; THROMBOCYTE COUNT; VALIDATION STUDY; CELL SEPARATION; CYTOLOGY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; FLOW CYTOMETRY; HEART INFARCTION; IMMUNOLOGY; REPRODUCIBILITY; STANDARD;

ANTIGENS, CD34; BONE MARROW CELLS; CELL SEPARATION; FLOW CYTOMETRY; LABORATORY TECHNIQUES AND PROCEDURES; MYOCARDIAL INFARCTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 34247173641     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240601052734     Document Type: Article

References (30)

1. Orlic, D., Kajstura, J. and Chimenti, S. (2003) Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant, 7, pp. 86-88.
2. Orlic, D., Kajstura, J. and Chimenti, S. (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA, 98, p. 10344.
3. Chan, RJ and Yoder, MC. (2004) The multiple facets of hematopoietic stem cells. Curr Neurovasc Res, 1, pp. 197-206.
4. Shah, RV and Mitchell, RN. (2005) The role of stem cells in the response to myocardial and vascular wall injury. Cardiovasc Pathol, 14, pp. 225-231.
5. Fernandez-Aviles, F., Roman, JA San and Garcia-Frade, J. (2004) Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res, 95, pp. 742-748.
6. Kajstura, J., Rota, M. and Whang, B. (2005) Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res, 96, pp. 127-137.
7. Kamihata, H., Matsubara, H. and Nishiue, T. (2001) Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation, 104, pp. 1046-1052.
8. Kawamoto, A., Tkebuchava, T. and Yamaguchi, J. (2003) Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation, 107, pp. 461-468.
9. Kawamoto, A., Gwon, HC and Iwaguro, H. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation, 103, pp. 634-637.
10. Orlic, D., Kajstura, J. and Chimenti, S. (2001) Bone marrow cells regenerate infarcted myocardium. Nature, 410, pp. 701-705.
11. Strauer, BE, Brehm, M. and Zeus, T. (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation, 106, pp. 1913-1918.
12. + cells enhance function and repair of the infarcted myocardium. Stem Cells, 24, pp. 772-780.
13. Murry, CE, Soonpaa, MH and Reinecke, H. (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature, 428, pp. 664-668.
14. Balsam, LB, Wagers, AJ and Christensen, JL (2004) Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature, 428, pp. 668-673.
15. Wollert, KC, Meyer, GP and Lotz, J. (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet, 364, pp. 141-148.
16. Schachinger, V., Assmus, B. and Britten, MB (2004) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol, 44, pp. 1690-1699.
17. Britten, MB, Abolmaali, ND and Assmus, B. (2003) Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): Mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation, 108, pp. 2212-2218.
18. Assmus, B., Schachinger, V. and Teupe, C. (2002) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation, 106, pp. 3009-3017.
19. Stamm, C., Westphal, B. and Kleine, HD (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet, 361, pp. 45-46.
20. Chen, SL and Fang, WW (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol, 94, pp. 92-95.
21. Kang, HJ, Kim, HS and Zhang, SY (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet, 363, pp. 751-756.
22. Bartunek, J., Vanderheyden, M. and Vandekerckhove, B. (2005) Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: Feasibility and safety. Circulation, 112, p. I178.
23. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Preservation, Storage and Distribution of Human Tissues and Cells.
24. 21 CFR Parts 16, 1270, and 1271 Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement; Final Rule.
25. Commission Directive 2005/28/EC of 8 April 2005 Laying Down Principles and Detailed Guidelines for Good Clinical Practice as Regards Investigational Medicinal Products for Human Use, as well as the Requirements for Authorisation of the Manufacturing or Importation of such Products (text with EEA relevance).
26. Commission Directive 2003/94/EC of 8 October 2003 Laying down the Principles and Guidelines of Good Manufacturing Practice in Respect of Medicinal Products for Human Use and Investigational Medicinal Products for Human Use (text with EEA relevance).
27. Commission Directive 91/356/EEC of 13 June 1991 Laying Down the Principles and Guidelines of Good Manufacturing Practice for Medicinal Products for Human Use.
28. Hofmann, M., Wollert, KC and Meyer, GP (2005) Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation, 111, pp. 2198-2202.
29. + blood cells. Blood, 87, pp. 4903-4909.
30. Serke, S. and Johnsen, HE. (2001) A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant, 27, pp. 463-470.